Table 1 Studies using antiviral therapy... | American Society of Hematology

Table 1

Studies using antiviral therapy in treating ATL

Country of origin	Therapy	No. of patients	ATL subtype	Disease status	Response to antiviral therapy	Survival	Reference
United Kingdom	IFN-α zidovudine	19	Acute: 17	All had disseminated disease; 7 refractory or relapsed after chemo	11 had major/partial response; 8 had minor/no response	Median survival: 3 mo	Gill et al, 1995⁸⁹
United Kingdom	IFN-α zidovudine	19	Lymph: 2		11 had major/partial response; 8 had minor/no response	Median survival: 3 mo	Gill et al, 1995⁸⁹
France	IFN-α zidovudine	5	Acute: 4	Newly diagnosed	2 had CR, 2 had 75% response, 1 had 50% response	Median survival: 10 mo	Hermine et al, 1995⁹⁰
France	IFN-α zidovudine	5	Smold: 1	Newly diagnosed	2 had CR, 2 had 75% response, 1 had 50% response	Median survival: 10 mo	Hermine et al, 1995⁹⁰
United Kingdom	CHOP, IFN-α zidovudine	15	Acute: 4	4 PD, 8 PR/CR, 3 untreated with active disease	67% PR; 26% NR	Median survival: 18 mo; 8 died 3-41 mon from diagnosis	Matutes et al, 2001⁹⁴
			Lymph: 2
			Smold: 2
United States	IFN-α zidovudine	18	Acute: 11	3 previously untreated; 15 relapsed or refractory	1 CR, 2 PR, 5 SD, 4 PD, 6 NE	Median survival: 6 mo	White et al, 2001⁹²
			Chronic: 2
			Lymph: 5
France	± CHOP, IFN-α zidovudine	19	Acute: 15	13 newly diagnosed; 6 had previous chemotherapy	47% CR, 21% PR, 21% NR, 11% NE	Median survival: 11 mo	Hermine et al, 2002⁹³
France	± CHOP, IFN-α zidovudine	19	Lymph: 4	13 newly diagnosed; 6 had previous chemotherapy	47% CR, 21% PR, 21% NR, 11% NE	Median survival: 11 mo	Hermine et al, 2002⁹³
French West Indies	CHOP, ± IFN-α, zidovudine ± dC + oral etoposide	29	Acute: 16	Newly diagnosed		Median survival: 8 mo (3 mo for CHOP vs 17 mo for CHOP + antiviral therapy)	Besson et al, 2002⁹⁶
			Chronic: 3
			Lymph: 10
Iran	IFN-α zidovudine	9	Acute: 3	8 previously untreated; 1 in relapse	4 CR, 3 PR, 2 PD	Median follow-up: 12 mo	Kchour et al, 2007¹⁰¹
			Chronic: 4
			Lymph: 2
United States + Carribbean	IFN-α + zidovudine	28	Acute: 15	21 previously untreated	22 evaluable (5 CR, 4 PR, 13 NR)	Median follow-up: 5.3 mo	Ramos et al, 2007¹⁰⁰
			Chronic: 3
			Lymph: 4
United States	EPOCH followed by IFN-α + zidovudine	6	All acute	Post-EPOCH: 1 in CR, 5 in PR	4 PD, 2 NE		Ratner et al, 2009⁹⁵
Iran	Arsenic trioxide, IFN-α + zidovudine	10	All chronic	Newly diagnosed	7 CR, 2 VGPR, 1 PR	Median follow-up: 8 mo	Kchour et al, 2009⁹⁹
Worldwide meta-analysis	First group: First-line antiviral therapy only (IFN-α + zidovudine); 2nd group: chemotherapy (CHOP) ± antiviral therapy	129	Acute: 73	Newly diagnosed	First-line antiviral therapy only: 35% CR, 31% PR, 34% NR	First group: 5-year OS of 46%; second group: 5-year OS of 12%.	Bazarbachi et al, 2010⁹⁷
			Chronic/smold:19
			Lymph: 37

Country of origin	Therapy	No. of patients	ATL subtype	Disease status	Response to antiviral therapy	Survival	Reference
United Kingdom	IFN-α zidovudine	19	Acute: 17	All had disseminated disease; 7 refractory or relapsed after chemo	11 had major/partial response; 8 had minor/no response	Median survival: 3 mo	Gill et al, 1995⁸⁹
United Kingdom	IFN-α zidovudine	19	Lymph: 2		11 had major/partial response; 8 had minor/no response	Median survival: 3 mo	Gill et al, 1995⁸⁹
France	IFN-α zidovudine	5	Acute: 4	Newly diagnosed	2 had CR, 2 had 75% response, 1 had 50% response	Median survival: 10 mo	Hermine et al, 1995⁹⁰
France	IFN-α zidovudine	5	Smold: 1	Newly diagnosed	2 had CR, 2 had 75% response, 1 had 50% response	Median survival: 10 mo	Hermine et al, 1995⁹⁰
United Kingdom	CHOP, IFN-α zidovudine	15	Acute: 4	4 PD, 8 PR/CR, 3 untreated with active disease	67% PR; 26% NR	Median survival: 18 mo; 8 died 3-41 mon from diagnosis	Matutes et al, 2001⁹⁴
			Lymph: 2
			Smold: 2
United States	IFN-α zidovudine	18	Acute: 11	3 previously untreated; 15 relapsed or refractory	1 CR, 2 PR, 5 SD, 4 PD, 6 NE	Median survival: 6 mo	White et al, 2001⁹²
			Chronic: 2
			Lymph: 5
France	± CHOP, IFN-α zidovudine	19	Acute: 15	13 newly diagnosed; 6 had previous chemotherapy	47% CR, 21% PR, 21% NR, 11% NE	Median survival: 11 mo	Hermine et al, 2002⁹³
France	± CHOP, IFN-α zidovudine	19	Lymph: 4	13 newly diagnosed; 6 had previous chemotherapy	47% CR, 21% PR, 21% NR, 11% NE	Median survival: 11 mo	Hermine et al, 2002⁹³
French West Indies	CHOP, ± IFN-α, zidovudine ± dC + oral etoposide	29	Acute: 16	Newly diagnosed		Median survival: 8 mo (3 mo for CHOP vs 17 mo for CHOP + antiviral therapy)	Besson et al, 2002⁹⁶
			Chronic: 3
			Lymph: 10
Iran	IFN-α zidovudine	9	Acute: 3	8 previously untreated; 1 in relapse	4 CR, 3 PR, 2 PD	Median follow-up: 12 mo	Kchour et al, 2007¹⁰¹
			Chronic: 4
			Lymph: 2
United States + Carribbean	IFN-α + zidovudine	28	Acute: 15	21 previously untreated	22 evaluable (5 CR, 4 PR, 13 NR)	Median follow-up: 5.3 mo	Ramos et al, 2007¹⁰⁰
			Chronic: 3
			Lymph: 4
United States	EPOCH followed by IFN-α + zidovudine	6	All acute	Post-EPOCH: 1 in CR, 5 in PR	4 PD, 2 NE		Ratner et al, 2009⁹⁵
Iran	Arsenic trioxide, IFN-α + zidovudine	10	All chronic	Newly diagnosed	7 CR, 2 VGPR, 1 PR	Median follow-up: 8 mo	Kchour et al, 2009⁹⁹
Worldwide meta-analysis	First group: First-line antiviral therapy only (IFN-α + zidovudine); 2nd group: chemotherapy (CHOP) ± antiviral therapy	129	Acute: 73	Newly diagnosed	First-line antiviral therapy only: 35% CR, 31% PR, 34% NR	First group: 5-year OS of 46%; second group: 5-year OS of 12%.	Bazarbachi et al, 2010⁹⁷
			Chronic/smold:19
			Lymph: 37

CHOP indicates cyclophosphamide, hydroxydaunorubicin, oncovin (vincristine), and prednisone; CR indicates complete response; ddC, zalcitabine; EPOCH, etoposide-vincristine-doxorubicin-cyclophosphamide-prednisone; lymph, ATL lymphoma; NE, not evaluated; NR, no response; PD, progressive disease; PR, partial response; SD, stable disease; smold, smoldering; and VGPR, very good partial response.

View Large

This Feature Is Available To Subscribers Only